CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s propr ...

CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement of in vivo preclinical proof of concept data and business development and financial updates. Webinar Presentation Details: The live and archived webcast of the Company's webinar presentation will be accessible through this webcast link, or through the Ev ...

Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%. The price fluctuation stands at 6.36%. According to recent financial reports, Editas Medicine generated $513,000 in revenue but reported a net loss of $67.61 million. The earnings per share stood at -$0.82, and the gross profit was -$907,000, resulting in a priceto-earnings ...

Editas Medicine, Inc. (NASDAQ:EDIT) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today. Question-and-Answer Sessio ...

Editas Medicine, Inc. (NASDAQ:EDIT) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it’s my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today. Question-and-Answer Sessio ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial. It has been about eight months since my previous Editas Medicine (NASDAQ: EDIT ) article , where I discussed the company's efforts to focus on their three key pillars of advancing reni-cel, progressing their invivo editing pipeline, and expanding busine ...

Editas Medicine, Inc. (NASDAQ:EDIT) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET Company Participants Gilmore O???Neill - CEO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald. So welcome to, the afternoon of day one of our Annual Healthcare Conference. With me today for this session is, Editas. We're delighted to have with us the company's Chie ...

Editas Medicine, Inc. (NASDAQ:EDIT) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody. I'm Terence Flynn, the U.S. Biopharma analyst here at Morgan Stanley, very pleased to be hosting Editas. Today from the company ...

Editas Medicine, Inc. (NASDAQ:EDIT) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O’Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody. I'm Terence Flynn, the U.S. Biopharma analyst here at Morgan Stanley, very pleased to be hosting Editas. Today from the company ...

Editas Medicine, Inc. (EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise the company's top line, were $0.5 million in the second quarter, down from $2.9 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. ...